CD274 and neoplasm: Nevertheless, anti-PD-1/PD-L1 therapies, while not yet FDA-approved for neuroblastoma (NB), have shown promise in preclinical studies, particularly when combined with agents such as anti-GD2 antibodies, dual checkpoint inhibitors, or CAR T cells, by improving the anti-tumor immune response [43,44,45].